Identification of Inhibitors and Drug Targets for Human Adenovirus Infections

Adenoviruses can cause infections in people of all ages at all seasons of the year. Adenovirus infections cause mild to severe illnesses. Children, immunocompromised patients, or those with existing respiratory or cardiac disease are at higher risk. Unfortunately, there are no commercial drugs or vaccines available on the market for adenovirus infections. Therefore, there is an urgent need to discover new antiviral drugs or drug targets for adenovirus infections. To identify potential antiviral agents for adenovirus infections, we screened a drug library containing 2138 compounds, most of which are drugs with known targets and past phase I clinical trials. On a cell-based assay, we identified 131 hits that inhibit adenoviruses type 3 and 5. A secondary screen confirmed the antiviral effects of 59 inhibitors that inhibit the replication of adenoviruses type 3 or 5. Most of the inhibitors target heat shock protein, protein tyrosine kinase, the mTOR signaling pathway, and other host factors, suggesting that these host factors may be essential for replicating adenoviruses. Through this study, the newly identified adenovirus inhibitors may provide a start point for developing new antiviral drugs to treat adenovirus infections. Further validation of the identified drug targets can help the development of new therapeutics against adenovirus infections.     

Early Age Shrinkage and Mechanical Effect of Ultra-High-Performance Concrete Composite Deck: A Case Study with In Situ Test and Numerical Simulation

For the Honghe Bridge project located in Yunnan Province, Southwest China, a steel/ultrahigh-performance concrete (UHPC) composite deck is used in the suspension bridge with a 700 m main span, and the steel stud connectors are used in the 50 mm–thick UHPC layer. To investigate the shrinkage behavior of UHPC and the relevant influence, the in situ time-dependent strain is measured continuously, and within the 20-day curing time, the material behavior is summarized based on test results. This paper proposes a prediction model for UHPC shrinkage which is refined from the widely used B3 model for normal concrete material, and the parameter values are modified and optimized by experimental comparison. Combining the numerical model and the finite element analysis model of the composite deck, the detailed mechanical state in structural parts is studied. For the practical construction, the simulation results indicate that the small thickness of UHPC above the stud and weak bond strength can influence the eventual structural performance greatly. In the discussion of stress distribution at different locations of the deck, the potential crack on the edge and the corner of the UHPC–steel interface and the mechanical damage on the stud connector around are also indicated.     

酸枣仁中黄酮类镇静催眠有效成分的研究

本文对辽宁产的酸枣仁中的黄酮类成分进行了初步研究,从中分离出一种淡黄色无定形粉末,经鉴定为黄酮碳甙(spinosin)。动物实验证明,酸枣仁中镇静催眠作用的成分不仅是皂甙成分,黄酮也是主要成分之一。     

驳骨煎剂促进骨折愈合的实验研究

为探讨驳骨煎剂促进骨折愈合的作用机理。选用体重２０－３０ｇ的ＮＩＨ小白鼠１２０只,雌雄各半,随机分为正常组,给药组、对照组。除正常组外,其它各组均采用定点手法折骨术造成小鼠右下肢胫骨中段闭合性骨折,术后７、１４、２１、２８天分批处死小鼠,处死前４８小时,经腹腔注射同一批号０．２ｍｌ＾４５Ｃａ－ＣａＣｌ２溶液,４８小时后,断头取向,并解剖出左右胫骨,测定骨痂生长状况及钙沉 积量的变化。结果显示,给药     

论中药工业中的中试放大验证

本文对中药制药工程技术的四要素之一-中药施工与验证进行探讨,从中药研究成果转化为大规模生产的过程中一般都将发生质的变化,许多重大工程技术问题也往往出现在这一阶段。因此,中试放大验证至关重要,也中药现代化的关键。本文论述了在实现中药大规模生产过程中进行中试放大验证的必要性,主要技术内容,应达到的目标,并就中试放大验证平台的建设,基本功能与任务,运行等进行了详细介绍。     

溶栓颗粒治疗急性缺血性中风68例临床研究

目的：观察溶栓颗粒治疗急性缺血性中风的疗效。方法：将128例急性缺血性中风患者随机分成3组,在一般内科治疗基础上分别口服溶栓颗粒（治疗组）、溶栓胶囊（对照组1）、尼莫地平（对照组2）,治疗3周,观察临床疗效。结果：治疗组临床疗效优于对照组1、对照组2（P〈0．05）,3组治疗后与治疗前比较症状均有明显改善（P〈0．05）,治疗组证候疗效优于对照组1、对照组2（P〈0．05）。结论：溶栓颗粒是治疗急性缺血性中风的有效药物。     

升麻甙与5-O甲基维斯阿米醇甙对血管内皮细胞分泌细胞因子的影响

目的:观察升麻甙与5-O甲基维斯阿米醇甙对氧化低密度脂蛋白(ox-LDL)致心脏微血管内皮细胞损伤,引起IL-6和TNF-α分泌的影响。方法:采用体外培养的乳鼠心脏微血管内皮细胞,测定其生长曲线及药物的最大无毒浓度后,经升麻甙(50、100、200μg/ml)与5-O甲基维斯阿米醇甙(50、100、200μg/ml)预处理24h,再与ox-LDL(MDA含量为3nmol/ml)共同孵育24h,用ELISA法和放免法分别检测细胞培养液中IL-6和TNF-α的水平。结果:升麻甙与5-O甲基维斯阿米醇甙在50、100、200μg/ml时能够明显抑制ox-LDL引起的内皮细胞IL-6、TNF-α分泌,且呈剂量依赖性。结论:升麻甙与5-O甲基维斯阿米醇甙能够抑制血管内皮细胞产生炎性细胞因子IL-6和TNF-α。     

Prospective pricing system by diagnosis-related groups: comparison of federal diagnosis-related groups with high-risk obstetric care groups

Of 468 diagnosis-related groups identified by the federal government for Medicaid reimbursement, 15 are related to obstetric hospital care. Each diagnosis-related group is considered a distinct group in which cases are homogeneous with respect to resource consumption. Because the diagnosis-related group system is based primarily on data from community and secondary care hospitals, it does not differentiate sufficiently among high-risk obstetric patients seen at tertiary care institutions, such as Florida's Regional Perinatal Intensive Care Centers. We developed an alternative scheme for diagnosis-related groups, called obstetric care groups, using the federal diagnosis-related groups as the model from which to depart. Data collected for 4192 women during a 2 1/2-year period indicate that obstetric care groups provide more homogeneous groups than diagnosis-related groups for our population of high-risk patients. The obstetric care groups differentiate between no complications, one complication, and two or more complications, while the diagnosis-related groups differentiate only between no complications and one or more complications. Also, complications for obstetric care groups are based on only 19 diagnoses that contribute significantly to resource consumption, while the list of possible complications exceeds 200 for diagnosis-related groups. Although the obstetric care group classification system is simpler than that for diagnosis-related groups, it results in a more accurate reimbursement of hospitalization charges for high-risk obstetric care.     

Chorionic villus sampling by rigid forceps: experience with 300 cases at risk for thalassemia major

In this article we report the results of chorionic villus sampling by a biopsy forceps inserted via the cervix under ultrasonic guidance in 300 pregnancies at risk for thalassemia major. A sufficient amount of chorionic villi for deoxyribonucleic acid analysis by oligonucleotide hybridization was obtained in all cases tested but one, with a success rate of 99.7%. The percentage of fetal loss, expressed as proportion of continuing pregnancies, was 4.8%. To verify the results, we carried out amniocyte deoxyribonucleic acid analysis in all the continuing pregnancies for the first 100 cases and in those in which trophoblast deoxyribonucleic acid analysis showed the heterozygous state for beta-thalassemia for the second 200 cases. At the beginning we had two cases of decidual contamination in such an amount to cause misdiagnosis. Successively more careful elimination of decidual tissue from villi avoided avoided this pitfall. These results indicate that chorionic villus sampling by a rigid forceps is a reliable and relatively safe method for fetal diagnosis of genetic diseases by deoxyribonucleic acid analysis.     

不同发育天数囊胚冻融移植后妊娠结局分析

目的比较不同发育天数冻融囊胚移植后的妊娠结局。方法回顾性分析1 176例行冻融囊胚移植患者的临床资料,其中植入前遗传学诊断(preimplantation genetic diagnosis,PGD)周期135例,比较第5日单囊胚移植(single embryo transfer,SET)组、双囊胚移植(double embryo transfer,DET)组与第6日SET组和DET组的妊娠结局。结果同是优质囊胚级别的条件下,第5日DET组的生化妊娠率(56.91%)、临床妊娠率(53.25%)以及多胎妊娠率(1.20%)显著高于其他组(P0.05);第5日DET组与SET组的胚胎着床率无统计学差异(P0.05),但均显著高于第6日DET组和SET组(P0.05);同级别以及PGD周期中第5日和第6日SET组相比较,第5日组的生化妊娠率、胚胎着床率均显著高于第6日组(P0.05)。结论在同是优质囊胚的条件下,第5日SET、DET及经PGD诊断的SET妊娠结局均优于第6日。